Public Profile

BioMarin

BioMarin Pharmaceutical Inc., headquartered in the United States, is a leading biotechnology company specialising in innovative therapies for rare genetic diseases. Founded in 1997, BioMarin has established itself as a pioneer in the industry, focusing on the development of enzyme replacement therapies and gene therapies that address unmet medical needs. With a strong presence in North America, Europe, and Asia, BioMarin's core products include treatments for conditions such as phenylketonuria (PKU) and mucopolysaccharidosis (MPS). The company is renowned for its commitment to research and development, which has led to several groundbreaking therapies that significantly improve patient outcomes. BioMarin's dedication to rare disease treatment has positioned it as a market leader, earning recognition for its innovative approach and impactful contributions to the biotechnology sector.

DitchCarbon Score

How does BioMarin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

BioMarin's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

BioMarin's reported carbon emissions

BioMarin, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without concrete figures or commitments, it is challenging to assess their carbon footprint or climate initiatives. However, the company is likely to be aware of the growing importance of sustainability and may be exploring strategies to address climate change in line with industry standards. As the biopharmaceutical sector increasingly focuses on reducing greenhouse gas emissions, BioMarin's future commitments and actions will be crucial in contributing to global climate goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. BioMarin's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. BioMarin is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

BioMarin is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Pharming Group N.V.

NL
Health and social work services (85)
Updated 6 days ago

Biogen

US
Research and development services (73)
Updated 6 days ago

Geron Corporation

US
Health and social work services (85)
Updated 6 days ago

Alnylam Pharmaceuticals

US
Medical, precision and optical instruments, watches and clocks (33)
Updated 6 days ago

Fulcrum Therapeutics, Inc.

US
Health and social work services (85)
Updated 2 days ago

BCR

CR
Fabricated metal products, except machinery and equipment (28)
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers